ENANTA PHARMACEUTICALS INC 8-K

What Happened
Enanta Pharmaceuticals announced that the U.S. Court of Appeals for the Federal Circuit has scheduled oral argument on its appeal of a patent-infringement suit against Pfizer for May 11, 2026. Enanta filed the notice of appeal on February 3, 2025, in its suit seeking damages for alleged infringement of U.S. Patent No. 11,358,953 related to Pfizer’s COVID-19 antiviral Paxlovid (nirmatrelvir tablets; ritonavir tablets). The company filed the current Form 8-K on March 26, 2026 noting the Court’s March 20, 2026 scheduling.

Key Details

• Enanta filed its notice of appeal on February 3, 2025.
• The appeal concerns alleged infringement of U.S. Patent No. 11,358,953 by Pfizer’s Paxlovid (nirmatrelvir; ritonavir).
• The Federal Circuit scheduled oral argument for May 11, 2026 (scheduling noted March 20, 2026).
• Enanta reported this development in an 8-K filed March 26, 2026.

Why It Matters
This is a procedural milestone in Enanta’s ongoing patent dispute with Pfizer. The scheduled oral argument is a key public court date where appellate judges will hear the parties’ positions; it may precede a written decision that could affect potential damages, licensing, or other remedies. For investors, the May 11, 2026 argument is the next material event to watch; future court rulings or settlement announcements could have financial or strategic implications for Enanta. The 8-K does not disclose any financial amounts or changes in management.